Eliyahou Harari, a principal owner controlling a 10% stake in CapsoVision, Inc. (CV), executed a significant equity acquisition on July 8, 2026, according to a recent Securities and Exchange Commission filing. The transaction involved the purchase of 81,300 shares of the company's common stock, with a total transaction value recorded at $495,117.
The shares were acquired at a unit price of $6.09. This acquisition price sits notably above the stock's current trading level of $5.99. Market data indicates that CapsoVision's equity has experienced substantial depreciation, having declined approximately 18% over the preceding week. Year-to-date performance shows an even steeper contraction, with shares down 44%. Following this recent transaction, Mr. Harari's indirect ownership position in CapsoVision has increased to 3,282,051 shares. The securities are held within the Harari Family Trust, for which Eliyahou Harari and his wife serve as trustees. The Form 4 documentation detailing this activity was submitted on July 10, 2026.
CapsoVision, which carries a market capitalization of $288 million, remains in an unprofitable financial state. The company reported earnings per share of -$0.75 over the last twelve months. Independent analysis suggests the stock is currently trading at a premium relative to its calculated Fair Value. Investors seeking comprehensive data on CapsoVision's financial standing can access a detailed Pro Research Report, which covers this equity and over 1,400 other US equities.
Recent corporate developments include the release of CapsoVision's first-quarter 2026 earnings, which failed to meet market expectations. The company posted an earnings per share of -$0.15, missing the forecasted figure of -$0.11 and resulting in a 36.36% negative surprise. Despite this financial miss, Benchmark has reiterated a Speculative Buy rating on CapsoVision, maintaining a price target of $10. The firm highlighted that the company's product development initiatives are progressing favorably, with anticipated regulatory submissions and clinical studies scheduled for the near future.
Corporate governance updates also include the appointment of Dr. David S. Shields to the Board of Directors. Dr. Shields, a seasoned gastroenterologist, has served as a clinical advisor to the company for nearly a decade. During the company's annual meeting, shareholders re-elected three Class I directors and ratified the appointment of the independent auditor. These actions reflect ongoing strategic and governance efforts within CapsoVision.
The equity is currently trading at $5.99, representing a change of +0.22 (+3.81%) from the previous close. After-hours trading shows the stock holding at $5.99. Data visualization tools indicate price movements across 1-day, 1-week, 1-month, 6-month, 1-year, 5-year, and maximum timeframes.
For traders evaluating the risk profile of CapsoVision, risk management strategies are available to determine entry points, stop-loss levels, and profit targets. These tools utilize advanced chart analysis to provide a complete risk management plan in under 60 seconds. Promotional offers for research services, including a July sale with a 60% discount on InvestingPro, are currently available.